Which funds are similar to Nippon India Pharma Fund Direct-Growth?
Funds similar to Nippon India Pharma Fund Direct-Growth in the Equity: Sectoral-Pharma category are listed in the Similar Funds tab, selected based on same category and benchmark index.
How does Nippon India Pharma Fund Direct-Growth compare to the category average?
The comparison of Nippon India Pharma Fund Direct-Growth against the Equity: Sectoral-Pharma category average — returns, alpha, beta and Sharpe — is shown in the Category vs Scheme Returns section at the top of the Similar Funds tab.
What is the rank of Nippon India Pharma Fund Direct-Growth in its category?
The rank of Nippon India Pharma Fund Direct-Growth within the Equity: Sectoral-Pharma category is shown in the Trailing Returns section on the Performance tab and the Similar Funds tab.
What are the alternatives to Nippon India Pharma Fund Direct-Growth?
Top alternatives to Nippon India Pharma Fund Direct-Growth in the Equity: Sectoral-Pharma category, sorted by AUM, are listed in the Similar Funds tab. Funds tracking the same benchmark — BSE Healthcare Total Return Index — are also listed separately.
How does Nippon India Pharma Fund Direct-Growth's expense ratio compare to similar funds?
The expense ratio of Nippon India Pharma Fund Direct-Growth is 1.00%. Over a 20-year investment, a 0.5% difference in expense ratio on a ₹10 lakh corpus can amount to lakhs in additional wealth creation.
How does Nippon India Pharma Fund Direct-Growth's AUM compare to similar funds?
Nippon India Pharma Fund Direct-Growth has an AUM of ₹ 9.04 k Cr. AUM reflects investor confidence. For small cap funds, very large AUM can limit portfolio flexibility.
Which fund has the best 3-year returns in the Equity: Sectoral-Pharma category?
The top-performing funds by 3-year returns in the Equity: Sectoral-Pharma category can be found by sorting the Similar Funds comparison table by the 3Y column.
Is Nippon India Pharma Fund Direct-Growth better than index funds in the same category?
Whether Nippon India Pharma Fund Direct-Growth beats index funds in the Equity: Sectoral-Pharma category can be assessed by comparing its trailing returns against the benchmark returns in the Performance tab. Nippon India Pharma Fund Direct-Growth has an alpha of -0.73%, indicating underperformance vs the benchmark. Historically, active funds in India have shown mixed results vs index funds — large cap active funds tend to underperform index funds over 10 years, while mid/small cap active managers have often added alpha.
How does Nippon India Pharma Fund Direct-Growth rank in risk-adjusted returns vs peers?
Nippon India Pharma Fund Direct-Growth has a Sharpe ratio of 1.00 and alpha of -0.73%. A Sharpe of 1.00 means the fund generates moderate returns per unit of risk. Risk-adjusted comparison across category peers — Sharpe, alpha and beta — is shown in the Alpha, Beta & Sharpe section of the Performance tab.
Are there any funds tracking BSE Healthcare Total Return Index with lower costs?
Funds tracking the same benchmark as Nippon India Pharma Fund Direct-Growth — BSE Healthcare Total Return Index — are listed in the Similar Funds tab. Compare their expense ratios to find the most cost-efficient option for the same index exposure.
